Clinical trials: Plasma Cell Myeloma Recurrent
Tumors, Lymphoma
Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)
Phase 1 trial to determine the safety, tolerability and maximum tolerated dose (MTD) of AP23573 in patients with refractory or recurrent malignancies, including myeloma and lymphoma.
- Conditions
- Tumors, Lymphoma, Multiple Myeloma
- Trial name
- NCT00060645
- Testing
- ridaforolimus
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma
SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
A Phase 1/2, Open Label Study of SL-401 in Combination with Pomalidomide and Dexamethasone In Relapsed and Refractory Multiple Myeloma
- Trial name
- NCT02661022
- Testing
- SL-401 7 µg/kg/day, SL-401 9 µg/kg/day
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Stemline Therapeutics, Inc.
Multiple Myeloma
A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE
The purpose of this study is to give patients who have had 4 or more prior lines of therapy for multiple myeloma access to VELCADE.
- Trial name
- NCT00063791
- Testing
- Bortezomib
- Where
- 3 sites in United States
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human BCMA Targeted T Cells Injection（BCMA CAR-T） Therapy for R/R MM.
- Trial name
- NCT05594797
- Testing
- Human BCMA Targeted T Cells Injection
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Multiple Myeloma
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study
The purpose of this study is to compare efficacy and safety of pomalidomide in combination with low-dose dexamethasone versus high-dose dexamethasone in subjects with refractory or relapsed and refractory multiple myeloma.
- Trial name
- NIMBUS (NCT01311687)
- Testing
- pomalidomide, Dexamethasone
- Where
- 94 sites in United States, Australia and 14 more
- Volunteers
- 455 people
- Sponsor
- Celgene
Relapsed/Refractory Multiple Myeloma
Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
This study is a single-armed, open-label, multicenter Phase 1/2 study to evaluate the efficacy and safety of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Equecabtagene Autoleucel) in subjects with…
- Trial name
- FUMANBA-04 (NCT07510100)
- Testing
- Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Eque-cel)
- Where
- 3 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Multiple Myeloma
IMGN901 in Combination With Lenalidomide and Dexamethasone
The purpose of this study is to test IMGN901 in combination with lenalidomide and dexamethasone every 28 days.
- Trial name
- NCT00991562
- Testing
- IMGN901
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- ImmunoGen, Inc.
Relapsed or Refractory Multiple Myeloma
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for EMB-06 and to characterize the safety and tolerability of EMB-06 at the RP2Ds.
- Trial name
- NCT04735575
- Testing
- EMB-06
- Where
- 10 sites in Australia, China
- Volunteers
- 40 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Multiple Myeloma
Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
For each subject the study will consist of two phases: a treatment phase and a follow-up phase. Screening procedures will take place within 28 days of baseline.
- Trial name
- NCT00065351
- Testing
- CC-5013
- Where
- 26 sites in United States
- Volunteers
- 222 people
- Sponsor
- Celgene
Relapsed or Plateau-Phase Multiple Myeloma
Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab
The purpose of this study is to determine if denosumab is effective in the treatment of relapsed or plateau-phase multiple myeloma.
- Trial name
- NCT00259740
- Testing
- DENOSUMAB
- Volunteers
- 96 people
- Sponsor
- Amgen
Multiple Myeloma
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Panobinostat (LBH589) is a highly potent pan-deacetylase inhibitor (pan-DACi), inclusive of HDAC6, which disrupts aggresome function, promotes accumulation of cytotoxic misfolded protein aggregates and triggers myeloma cell…
- Trial name
- PANORAMA-1 (NCT01023308)
- Testing
- Panobinostat, Bortezomib, Dexamethasone
- Where
- 210 sites in United States, Argentina and 32 more
- Volunteers
- 767 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed or Refractory Multiple Myeloma, Hematological Malignancy
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
This is a Phase 1a/1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG301 in Patients with Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
- Trial name
- NCT04684108
- Testing
- SG301
- Where
- 14 sites in China
- Volunteers
- 61 people
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
Relapsed or Refractory Multiple Myeloma
Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to establish the Recommended Phase 2 Dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antimyeloma activity of ORIC-533 in patients with multiple myeloma who have…
- Trial name
- NCT05227144
- Testing
- ORIC-533
- Where
- 8 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- ORIC Pharmaceuticals
Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory
BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against relapsed or refractory B cell non-Hodgkin lymphoma and multiple myeloma, however not all tumors respond or remain in response to CD19…
- Conditions
- Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Non-Hodgkin Lymphoma, B-cell
- Trial name
- NCT07771361
- Testing
- BAFF CAR-T
- Volunteers
- 90 people
- Sponsor
- Luminary Therapeutics
Multiple Myeloma (MM)
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
The main purpose of the study is to understand the safety and tolerability of cemsidomide when given along with elranatamab in subjects with relapsed or refractory multiple myeloma.
- Trial name
- NCT07280013
- Testing
- Cemsidomide, Elranatamab
- Where
- 19 sites in United States
- Volunteers
- 60 people
- Sponsor
- C4 Therapeutics, Inc.
Multiple Myeloma
A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure
The purpose of this observational study is to assess HRQoL in relapsed and/or refractory multiple myeloma (RRMM) participants who have previously received a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38…
- Trial name
- NCT05217082
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma, Relapsed and Refractory Multiple Myeloma
A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma
This study is designed to evaluate the tolerability and safety of HG146 capsule in patients with multiple myeloma.
- Trial name
- NCT03710915
- Testing
- HG146
- Where
- China
- Volunteers
- 3 people
- Sponsor
- HitGen Inc.
Advanced Solid Tumors, Lymphoma
A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
This is a first-time-in-human (FTIH), Phase 1 study to determine the safety, tolerability, maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and pharmacokinetics (PK) of AZD0466 in patients with solid tumors…
- Conditions
- Advanced Solid Tumors, Lymphoma, Multiple Myeloma, Hematologic Malignancies
- Trial name
- NCT04214093
- Testing
- AZD0466
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- AstraZeneca
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma
This is a Phase I dose-escalation study to evaluate the safety, tolerability and preliminary efficacy of an autologous BCMA-targeting RNA-engineered CAR T-cell therapy in patients with Relapsed/Refractory Multiple Myeloma.
- Trial name
- DC15-MM-01 (NCT06304636)
- Testing
- Descartes-15
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Cartesian Therapeutics